Mildly Cross-Linked Dendrimer Hydrogel Prepared via Aza-Michael Addition Reaction for Topical Brimonidine Delivery

Abstract

In this work, we developed a mildly cross-linked dendrimer hydrogel (mcDH) via aza-Michael addition of polyamidoamine PAMAM dendrimer G5 and polyethylene glycol diacrylate PEG-DA, Mn = 575 g/mol . We chose the antiglaucoma drug brimonidine tartrate as a model drug and developed a new antiglaucoma drug formulation on the basis of mcDH. Cytotoxicity of the mcDH formulation to NIH3T3 fibroblasts, in vitro drug release kinetics and ex vivo drug permeability across the rabbit cornea were examined. We also studied interactions between PAMAM dendrimer and the drug using 1H NMR spectroscopy for a mechanistic understanding of brimonidine release from the mcDH. mcDH was found to be efficient unionizing brimonidine tartrate to form and encapsulate brimonidine free base for sustained release and enhanced corneal permeation.

Department(s)

Chemical and Biochemical Engineering

Comments

This work was supported by the National Institutes of Health (R01EY024072).

Keywords and Phrases

Brimonidine tartrate; Dendrimer hydrogel; Glaucoma; Topical formulation

International Standard Serial Number (ISSN)

1550-7033; 1550-7041

Document Type

Article - Journal

Document Version

Citation

File Type

text

Language(s)

English

Rights

© 2017 American Scientific Publishers, All rights reserved.

Publication Date

01 Sep 2017

PubMed ID

29479294

Link to Full Text

Share

 
COinS